BILL · 2013–14 SESSION

HB 2326: Biological products prescrip

Concerning the prescription of biological products.

Summary

  • Authorizes biosimilar products to be substituted in the place of a biological product if the United States Food and Drug Administration has determined that the biosimilar product is interchangeable with the biological product.
  • Requires pharmacists dispensing biological products to record the name of the product and the manufacturer in an interoperable health records system that is shared with the prescribing provider or to communicate it directly to the prescribing provider.

From the House Bill Report (HB 2326), written by the Legislature's nonpartisan staff. Read the full report ↗

Did not pass Did not pass · stalled on the House floor
  1. IntroducedJan 15, 2014
  2. Out of committeeFeb 10, 2014
  3. Passed Housestopped here
  4. Passed Senate
  5. Governor
  6. Law
Prime sponsor
Eileen Cody (D-34)
Introduced
January 15, 2014 in the House
Last action
February 18, 2014
Companion bill
SB 6091
Budget
Has a fiscal note

AN ACT Relating to the prescription of biological products and interchangeable biological products;

Sponsors

Votes

No recorded floor votes.

History

  1. Returned to Rules Committee for second reading.
  2. Placed on second reading by Rules Committee.
  3. Passed to Rules Committee for second reading.
  4. Committee relieved of further consideration.
  5. Committee relieved of further consideration.
  6. Passed to Rules Committee for second reading.
  7. Committee relieved of further consideration.
  8. First reading, referred to Health Care & Wellness (Not Officially read and referred until adoption of Introduction report).

HB 2326 in other sessions

Bill numbers restart every two years, so the same number is a different bill in each session.

Report wrong or missing information on this page